Louisiana HB1199 mandates health insurance coverage for genetic testing and treatment of SCN2A-associated medical conditions.

HB1199 requires health coverage plans to provide insurance coverage for genetic testing to diagnose SCN2A-associated medical conditions and for medically necessary treatments related to these conditions. The law defines terms such as "genetic testing" and "medically necessary treatment." It mandates coverage for treatments including anti-seizure medications, rehabilitative services, and nutritional management. The provisions apply to health coverage plans delivered, issued for delivery, renewed, or contracted in Louisiana on or after January 1, 2027.

Louisiana HB1199 mandates health insurance coverage for genetic testing and treatment of SCN2A-associated medical conditions.

HB1199 requires health coverage plans to provide insurance coverage for genetic testing to diagnose SCN2A-associated medical conditions and for medically necessary treatments related to these conditions. The law defines terms such as "genetic testing" and "medically necessary treatment." It mandates coverage for treatments including anti-seizure medications, rehabilitative services, and nutritional management. The provisions apply to health coverage plans delivered, issued for delivery, renewed, or contracted in Louisiana on or after January 1, 2027.